Compare TRAK & ABEO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TRAK | ABEO |
|---|---|---|
| Founded | 1990 | 1974 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 245.1M | 281.0M |
| IPO Year | 1998 | 1980 |
| Metric | TRAK | ABEO |
|---|---|---|
| Price | $12.25 | $5.32 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $18.20 |
| AVG Volume (30 Days) | 96.1K | ★ 1.1M |
| Earning Date | 02-11-2026 | 11-12-2025 |
| Dividend Yield | ★ 0.65% | N/A |
| EPS Growth | ★ 19.98 | N/A |
| EPS | 0.36 | ★ 1.29 |
| Revenue | ★ $23,136,391.00 | $400,000.00 |
| Revenue This Year | $8.29 | N/A |
| Revenue Next Year | $24.17 | $1,589.77 |
| P/E Ratio | $34.36 | ★ $4.10 |
| Revenue Growth | ★ 11.05 | N/A |
| 52 Week Low | $11.98 | $3.93 |
| 52 Week High | $23.72 | $7.54 |
| Indicator | TRAK | ABEO |
|---|---|---|
| Relative Strength Index (RSI) | 30.98 | 54.91 |
| Support Level | $12.91 | $4.80 |
| Resistance Level | $13.48 | $5.55 |
| Average True Range (ATR) | 0.53 | 0.24 |
| MACD | -0.05 | 0.01 |
| Stochastic Oscillator | 16.32 | 66.03 |
ReposiTrak Inc is a software-as-a-service (SaaS) company based in Murray, Utah, specializing in supply chain management solutions for retailers, suppliers, and wholesalers, prominently in the food industry. The company offers three main product suites: ReposiTrak Compliance Management, ReposiTrak Traceability Network, and ReposiTrak Supply Chain Solutions. These platforms help customers comply with food safety regulations, manage supplier compliance documentation, trace products through the supply chain, and optimize supply chain operations. The company derives revenue from five sources: (i) subscription fees, (ii) transaction-based fees, (iii) professional services fees, (iv) license fees, and (v) hosting and maintenance fees.
Abeona Therapeutics Inc is a clinical-stage biopharmaceutical company. The firm is focused on developing gene therapies and plasma-based products for life-threatening rare genetic diseases. Its clinical programs consist of pz-cel, an autologous, engineered cell therapy currently in development for recessive dystrophic epidermolysis bullosa (RDEB). The Company's development portfolio also features adeno-associated virus (AAV)-based gene therapies designed to treat unmet, medically needed ophthalmic diseases using the novel.